Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
View Patent ↗A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
1. A method of generating a mammalian immune response directed to 158P1D7 (SEQ ID NO: 657), comprising:
providing an immunogenic composition comprising SEQ ID NO: 657; and
exposing the mammal's immune system to the immunogenic composition whereby an immune response to SEQ ID NO: 657 is generated.
2. A method of inducing an immune response to a 158P1D7 protein (SEQ ID NO: 657), comprising:
providing an immunogenic composition comprising SEQ ID NO: 657; and
contacting an antigen presenting cell with the immunogenic composition, whereby an immune response to SEQ ID NO: 657 is induced.
3. The method of claim 2 , wherein the immune response comprises the antigen-presenting cell presenting an antigen of SEQ ID NO: 657 to a B cell, whereby the B cell is induced to generate an antibody that specifically binds to SEQ ID NO: 657.
4. The method of claim 2 , wherein the immune response comprises the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a cytotoxic T cell (CTL), whereby the CTL is induced to kill an autologous cell that expresses the protein encoded by SEQ ID NO: 657.
5. The method of claim 2 , wherein the immune response comprises the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a helper T cell (HTL), whereby the HTL is induced to secrete a cytokine that facilitates the cytotoxic activity of a CTL or the antibody producing activity of a B cell.
6. The method of claim 1 , wherein the exposing step comprises administering a nucleotide sequence comprising SEQ ID NO: 656.
7. The method of claim 1 , wherein the immune response comprises the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a B cell, whereby the B cell is induced to generate an antibody that specifically binds to the protein encoded by SEQ ID NO: 657.
8. The method of claim 1 , wherein the immune response comprises the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a cytotoxic T cell (CTL), whereby the CTL is induced to kill an autologous cell that expresses the protein encoded by SEQ ID NO: 657.
9. The method of claim 1 , wherein the immune response comprises the antigen presenting cell presenting an antigen of SEQ ID NO: 657 to a helper T cell (HTL), whereby the HTL is induced to secrete a cytokine that facilitates the cytotoxic activity of a CTL or the antibody producing activity of a B cell.